Equities

Unicocell Biomed Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
6794:TAI

Unicocell Biomed Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (TWD)87.00
  • Today's Change0.10 / 0.12%
  • Shares traded23.55k
  • 1 Year change+27.01%
  • Beta0.2516
Data delayed at least 20 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of TWD
(except for per share items)
Fiscal data as of Dec 31 2024202420232022
ASSETS
Cash And Short Term Investments550477214
Total Receivables, Net8.026.462.02
Total Inventory7.785.456.17
Prepaid expenses201716
Other current assets, total6.290.240.06
Total current assets592507238
Property, plant & equipment, net155176174
Goodwill, net------
Intangibles, net0.340.330.36
Long term investments29----
Note receivable - long term------
Other long term assets1.682.392.15
Total assets778686414
LIABILITIES
Accounts payable1.970.110.91
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases6.226.095.93
Other current liabilities, total19119.70
Total current liabilities271717
Total long term debt626861
Total debt687467
Deferred income tax------
Minority interest------
Other liabilities, total4.134.353.26
Total liabilities938980
SHAREHOLDERS EQUITY
Common stock584557424
Additional paid-in capital706552338
Retained earnings (accumulated deficit)(605)(512)(428)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity685596334
Total liabilities & shareholders' equity778686414
Total common shares outstanding585642
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.